Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Liebel-Flarsheim Company LLC
WARNING LETTER
•Liebel-Flarsheim Company LLC•April 8, 2025

Liebel-Flarsheim Company LLC – FDA Warning Letter, Apr 8, 2025

Record Details

The FDA issued a Warning Letter to Liebel-Flarsheim Company LLC following an inspection from March 25 to April 8, 2025, at their Raleigh, NC, drug manufacturing facility. The letter cites significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211), rendering their drug products adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. Significant issues included the failure to thoroughly investigate unexplained discrepancies and batch failures.

Specifically, the company inadequately investigated numerous microbial excursions (bioburden) in in-process drug samples and out-of-specification (OOS) endotoxin results for finished sterile drug products. Investigations frequently lacked scientifically justified root causes, often concluding as "root cause undetermined," and corrective actions were deemed insufficient. The FDA criticized the firm"s over-reliance on terminal sterilization and final product testing as a substitute for comprehensive root cause analysis. Notably, the company released batches with OOS endotoxin failures for U.S. distribution.

As a required action, the FDA demands a retrospective, independent review of all invalidated OOS results, including those from in-process and release/stability testing, to address these critical deficiencies and ensure product safety.

Company
Liebel-Flarsheim Company LLC
Inspection date
April 8, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 405244c0-775e-4179-820d-d13e0d032dca

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21121 CFR 211.42(c)21 CFR 211.3421 CFR 210FD&C Act 501(a)(2)(B)21 CFR 211.19221 CFR 211.63

Full citation text and observation details available on the Dashboard.

Other documents for Liebel-Flarsheim Company LLC
  • 483 - 2025-04-08April 8, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Liebel-Flarsheim Company LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.